Improving the longevity of oesophageal stents

提高食管支架的使用寿命

• 批准号: 2590424
• 金额: --
• 依托单位: University of Manchester
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2590424
• 关键词: Improving; longevity; oesophageal; stents

Cancer Research UK describes 9,200 new cases of oesophageal cancer per year in 2017. 70% are diagnosed at a late stage, being incurable and causing 7,925 deaths / year. Treatments using chemotherapy and radiotherapy - and more recently hormone therapy - have improved patient survival in recent years, extending survival of stent patients after receiving a stent from an average of 3months in 2004 to currently 15-18months. Most oesophageal cancers present late and are not curable and most patients eventually require insertion of a stent (most commonly a nitinol stent) to keep the lumen of the oesophagus and allow the patient to continue to eat. These stents were originally designed for use in blood vessels but have been adapted for use in the gastro-intestinal tract and oesophagus therefore subjecting the stents to a different working environment especially chemical, due to exposure of the low pH of gastric acid, but also mechanical due to the movement and compression of oesophageal function (peristalsis). As a consequence an increasing number of patients experience device failure, requiring repeat procedures. The re-intervention rate at 6months reaches 60%, which is now resulting in increased stent failures, which necessitate further procedures, and puts the patient at additional risk.By improving the properties of these nitinol stents, we can improve their working life and remove the need for removal and replacement. This will improve clinical outcome and patient experience and reduce the need for repeat procedures and the associated costs to the NHS.

英国癌症研究中心称，2017年每年有9200例食管癌新病例。70%在晚期被诊断出来，无法治愈，每年造成7,925人死亡。近年来，化疗和放疗以及最近的激素治疗改善了患者的生存，使接受支架的患者的生存期从2004年的平均3个月延长到目前的15-18个月。大多数食管癌出现较晚且无法治愈，大多数患者最终需要植入支架（最常见的是镍钛诺支架）以保持食道腔，使患者能够继续进食。这些支架最初是为血管设计的，但已经适应了胃肠道和食道的使用，因此将支架置于不同的工作环境中，特别是由于暴露于胃酸的低pH值而产生的化学作用，但也由于食管功能（蠕动）的运动和压迫而产生的机械作用。因此，越来越多的患者经历器械故障，需要重复手术。6个月时的再干预率达到60%，这导致支架失效增加，这需要进一步的手术，并使患者面临额外的风险。通过改善这些镍钛诺支架的性能，我们可以提高它们的工作寿命，并消除拆卸和更换的需要。这将改善临床结果和患者体验，减少重复手术的需要和NHS的相关费用。